Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors
"We are pleased and honored to have our new directors join the Revagenix board.
- "We are pleased and honored to have our new directors join the Revagenix board.
- These additions will bolster and complement our leadership team's extensive experience in anti-infectives to address the scientific and commercial challenges in the field."
- The Series B financing complements ongoing funding from two product development contracts with the National Institute of Allergy and Infectious Diseases (NIAID).
- As part of this transition, two former directors, Andrew Calabrese and Aleks Engel will step down from the board.